Synthesis and pharmacological evaluation of pyrroloazepine derivatives as potent antihypertensive agents with antiplatelet aggregation activity

Chemical and Pharmaceutical Bulletin

Volumn 47, Issue 2, 1999, Pages 246-256

  Mizuno, Akira ^a   Inomata, Norio ^a   Miya, Mikiko ^a   Kamei, Tomoe ^a   Shibata, Makoto ^a   Tatsuoka, Toshio ^a   Yoshida, Maki ^a   Takiguchi, Chikako ^a   Miyazaki, Tomoko ^a  

^a SUNTORY LTD   (Japan)

Author keywords

Antihypertension; Antiplatelet aggregation; Pyrrolo 2,3 c azepine; Serotonin 2 antagonist; SUN9221; 1 adrenergic antagonist

Indexed keywords

1 [4 [4 (4 FLUOROBENZOYL)PIPERIDINO]BUTYL] 4 HYDROXYIMINO 7 METHYL 1,4,5,6,7,8 HEXAHYDROPYRROLO[2,3 C]CLAZEPIN 8 ONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DRUG CONFORMATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0032915720     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.47.246     Document Type: Article

References (54)

1. For a review on coronary heart diseases, see: Am. J. Med. 76 (2A) (1984).
2. Weinberger M. H., Arch. Intern. Med., 145, 1102-1105 (1985).
3. a) Cambridge D., Davey M. J., Massingham R., Br. J. Pharmacol., 59, 514P-515P (1977);
4. b) Vincent J., Elliot H. L., Meredith P. A., Reid J. L., Br. J. Clin. Pharmacol., 15, 719-725 (1983).
5. a) Lowenstein J., Neusy A. -J., Am. J. Med., 76, 79-84 (1984);
6. b) Ames R. P., Kiyasu J. Y., J. Clin. Pharmacol., 29, 123-127 (1989).
7. a) Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure, Arch. Intern. Med., 153, 154-183 (1993);
8. b) Guidelines Sub-Committee, J. Hypertens., 11, 905-918 (1993).
9. a) Mehta J., Mehta P., Am J. Cardiol., 47, 331-334 (1981);
10. b) Lande K., Os I., Kjeldsen S. E., Westheim A., Hjermann I., Eide I., Gjesdal K., J. Hypertens., 5, 401-406 (1987);
11. c) Fetkovska N., Amstein R., Ferracin F., Regenass M., Buhler F.-R., Pletscher A., Hypertension, 15, 267-273 (1990).
12. Vanhoutte P. M., Fed. Proc., 42, 233-237(1983).
13. a) De Clerck F., David J. -L., Janssen P. A. J., Agents Actions, 12, 388-397 (1982);
14. b) De Clerck F., van Nueten J. M., Reneman R. S., ibid., 15, 612-626 (1984);
15. c) van Nueten J. M., Fed. Proc., 42, 223-227 (1983);
16. d) De Clerck F., Herman A. G., ibid., 42, 228-232 (1983).
17. a) Sigal S. L., Gellman J., Sarembock I. J., LaVeau P. J., Chen Q. S., Cabin H. S., Ezekowitz M. D., Arterioscler. Thromb., 11, 770-783 (1991):
18. b) Golino P., Piscione F., Willerson J. T., Cappelli-Bigazzi M., Focaccio A., Villari B., Indolfi C., Russolillo E., Condorelli M., Chiariello M., New Eng. J. Med., 324, 641-648 (1991);
19. c) Shimokawa H., Vanhoutte P. M., J. Am. Coll. Cardiol., 17, 1197-1202 (1991);
20. d) Crowley S. T., Dempsey E. C., Horwitz K. B., Horwitz L. D., Circulation, 90, 1908-1918 (1994).
21. Symoens J., Janssens M., Drug Dev. Res., 8, 159-172 (1986).
22. a) van de Wal H. J., Wijn P. F., van Lier H. J., Skotnicki S. H., Microcirc: Endothelium Lymphatics, 2, 657-685 (1985);
23. b) Bush L. R., J. Pharmacol. Exp. Ther., 240, 674-682 (1987).
24. a) Fozard J. R., J. Cardiovasc. Pharmacol., 4, 829-838 (1982);
25. b) Cohen M. L., Fuller R. W., Kurz K. D., Hypertension, 5, 676-681 (1983).
26. a) Nagano H., Tagaki M., Kubodera N., Matsunaga I., Nabata H., Ohba Y., Sakai K., Hata S., Uchida Y., Eur. Pat. 89065 (1983) [Chem. Abstr., 100, 6547 (1984)];
27. a) Nagano H., Tagaki M., Kubodera N., Matsunaga I., Nabata H., Ohba Y., Sakai K., Hata S., Uchida Y., Eur. Pat. 89065 (1983) [Chem. Abstr., 100, 6547 (1984)];
28. b) Imagawa J., Sakai K., Eur. J. Pharmacol., 131, 257-264 (1986).
29. Russo F., Romeo G., Guccione S., De Blasi A., J. Med. Chem., 34, 1850-1854 (1991).
30. Chern J.-W., Tao R-L., Yen M.-H., Lu G.-Y., Shiau C.-Y., Lai Y.-J., Chien S.-L., Chan C.-H., J. Med. Chem., 36, 2196-2207 (1993).
31. Russell R. K., Press J. B., Rampulla R. A., McNally J. J., Falotico R., Keiser J. A., Bright D. A., Tobia A., J. Med. Chem., 31, 1786-1793 (1988).
32. Kobayashi J., Ohizumi Y., Nakamura H., Hirata Y., Wakamatsu K., Miyazawa T., Experientia, 42, 1064-1065 (1986).
33. a) Sharma G. M., Buyer J. S., Pomerantz M. W., J. Chem. Soc., Chem. Comm., 1980, 435-436;
34. b) Kitagawa I., Kobayashi M., Kitanaka K., Kido M., Kyogoku Y., Chem Pharm. Bull., 31, 2321-2328 (1983);
35. c) De Nanteuil G., Ahond A., Guilhem J., Poupat C., Tran Huu Dau E., Potier P., Pusset M., Pusset J., Laboute P., Tetrahedron, 41, 6019-6033 (1985).
36. Schmitz F. J., Gunasekera S. P., Lakshmi V., Tillekeratne L. M. V., J. Nat. Prod., 48, 47-53 (1985).
37. 3 in boiling acetone.
38. We previously reported the alternative synthetic method for the preparation of 9a and 9g, see: Cho H., Matsuki S., Mizuno A., Annoura H., Tatsuoka T., J. Heterocyclic Chem., 34, 87-91 (1997).
39. a Shioiri T., Yokoyama Y., Kasai Y., Yamada S., Tetrahedron, 32, 2211-2217 (1976);
40. b) Takuma S., Hamada Y., Shioiri T., Chem. Pharm. Bull., 30, 3147-3153 (1982) and references therein.
41. The yield of this method is generally lower than that of the PPA method.
42. 1H-NMR data of both isomers. For instance, the signal of the C-3 methine proton of 14a′ appeared at δ 7.04, and this was shifted to a lower field compared to that of 14a (δ 6.38) by anisotropic effect of the oxygen atom on the oxime moiety.
43. a) Buffolo R. R., Waddell J. E., Yaden E. L., J. Pharmacol. Exp. Ther., 221, 309-314 (1982);
44. b) Jenkin R. A., Baldi M. A., Iwanov V., Moulds R. F. W., J. Cardiovasc. Pharmacol., 18, 566-573 (1991);
45. c) Itoh T., Kitamura K., Kuriyama H., J. Physiol. (Lond), 345, 409-422 (1983);
46. d) Ishikawa S., Jpn. J. Pharmacol. 35, 19-25 (1984);
47. e) Fujii K., Kuriyama H., J. Pharmacol. Exp. Ther., 235, 764-770 (1985).
48. Holly R. W., Holly A. D., J. Am. Chem. Soc., 71, 2124-2129 (1949).
49. Adamson D. W., J. Chem. Soc., 1949, S144-S155.
50. Leonard N. J., Fischer F. E., Barthel E., Jr., Figueras J., Jr., Wildman W. C., J. Am. Chem. Soc., 73, 2371-2373 (1951).
51. Stork G., McElvain S. M., J. Am. Chem. Soc., 69, 971-972 (1947).
52. Desai M., Watthey J. W. H., Zuckerman M., Org. Prep. Proc. Int., 8, 85-86 (1976).
53. Duncan R. L., Jr., Helsley G. C., Welstead W. J., Jr., DaVanzo J. P., Funderburk W. H., Lunsford C. D., J. Med. Chem., 13, 1-6 (1970).
54. Schnell C. R. Wood J. M., Am J. Physiol., 264, H1509-H1516 (1993).